Posts tagged with "NYSE:PFE"

Pfizer Inc (NYSE:PFE) Announces Results Of Two Phase-III Clinical Trials

Posted by Nathan Alexander October 14, 2013 0 Comment 2436 views

Last week, Pfizer Inc. (NYSE:PFE) announced top line results from 2 different Phase-III clinical trials of the novel oral Janus kinase-inhibitor, tofacitinib. This is being investigated to be used for treating adults who suffer from moderate to severe chronic plaque-psoriasis. These are the first 2 of the 5 different studies that are part of the […]

Pfizer Inc (NYSE:PFE) Gets Approval For Menopause Drug

Posted by Lynn Eisler October 6, 2013 0 Comment 2587 views

The U.S Food Drug Administration has approved Duavee, Pfizer Inc (NYSE:PFE)’s menopause drug. The company says that this drug will help in reducing hot-flashes and have lesser side-effects than existing hormone replacement therapies. FDA approval On Thursday, the FDA said that it had approved the drug to be used by women suffering from moderate-to-severe menopause […]

Will Pfizer Inc (NYSE:PFE) Turnaround?

Posted by Kristi Scott October 2, 2013 0 Comment 1497 views

Pfizer Inc (NYSE:PFE) has announced that Shantanu Narayen has been elected to its Board of Directors. The effective start date of his appointment is 27 September 2013. Narayen has also been appointed to the company’s Corporate Governance & Science and Technology Committees Impressive run The 50-year old Narayen is the president and CEO of Adobe […]

Can Pfizer Inc (NYSE:PFE) Cure Arthritis?

Posted by Michael Korte September 24, 2013 0 Comment 2576 views

Early today morning, Pfizer Inc (NYSE:PFE)  announced that it will be presenting results of tests conducted on its XELJANZ target drug which is designed to treat arthritis at the American college of Rheumatology in 2013 annual meeting. The company share price is up by $0.11 from its previous day close of $28.80. It is currently […]

Pfizer Inc (NYSE:PFE)’s Aricept intercepts Alzheimer’s market

Posted by Ryan Mandell August 26, 2013 0 Comment 2102 views

Pfizer Inc (NYSE:PFE) stock gained 0.64% in Friday’s trading session. The opening price of the shares was $28.14 which touched an intraday high of $28.36 and close at $28.34. More than 18.51 million shares exchanged hands in Friday’s trading session while the average volume of shares traded over 30 days was 27.06 million. The company […]

Pfizer Inc (NYSE:PFE) will retain its fizz in 2013

Posted by Nathan Alexander August 6, 2013 0 Comment 4118 views

Over the past ten years, healthcare has been one domain that has managed to sustain its momentum in the market. As per the IMS, from 2011-2016, spending on healthcare is projected to rise at a CAGR of approximately 6%. The volume-growth for pharmaceutical companies in emerging markets and the steady rise in medicine spending in […]

Pfizer Inc (NYSE:PFE) demerging “innovation” and “value”

Posted by Nathan Alexander July 30, 2013 0 Comment 901 views

Pfizer Inc (NYSE:PFE) is all set to spin-of its generic-drug business. It has now also announced that it plans on segregating the company’s commercial operations into 2 units. This is primarily for patent-protected brands. A third segment will consist of generics. PFE is the largest drugmaker in the U.S and said that the changes will […]

Onyx not precious to Pfizer Inc (NYSE:PFE) anymore

Posted by Samantha Donahue July 22, 2013 0 Comment 1895 views

This week, Pfizer Inc (NYSE:PFE) has reverted from its decision of bidding for Onyx Pharmaceuticals. The path is now clear for Amgen and it can move forth with its acquisition plans. Onyx had announced its sell-out plan on 30 June and the company is valued at close to $9.3B. Onyx had rejected the $120/share bid […]

Pfizer Inc (NYSE:PFE) “Amplify”ing benefits of Eliquis

Posted by Samantha Donahue July 5, 2013 0 Comment 2311 views

Pfizer Inc (NYSE:PFE) and Bristol-Myers Squibb said that Eliquis, their blood thinner has met key goals in the study that evaluated the treatment of dangerous clots. This has paved the way for them to seek further regulatory approval. Eliquis is one of a new wave of orally-administered anti-clotting drugs that is supposed to replace warfarin, […]

Pfizer Inc (NYSE:PFE) may want Onyx to adorn its crown

Posted by Lynn Eisler July 2, 2013 0 Comment 2339 views

Pfizer Inc (NYSE:PFE) has shown interest in buying-out Onyx a biotech company whose cancer drugs have a very promising revenue stream. Apart from Pfizer, Novartis has also shown an interest in the company. Onyx has a market value of approximately $9.5B and put itself up for a buy-out on Sunday. It cited certain “expressions of […]